--- title: "Belite Bio (BLTE) news: offering" url: "https://aibio.space/companies/belite-bio/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "BLTE offering news: Belite Bio says it completed a $402 million public offering of ADSs. Belite Bio, Inc (NASDAQ: BLTE), United States." --- BLTE Belite Bio, Inc NASDAQ · United States # Belite Bio (BLTE) news BLTE offering news Financings · 2026-03-02 ## [Belite Bio says it completed a $402 million public offering of ADSs](https://aibio.space/news/belite-bio-says-completed-402-million-public-offering-adss/) Belite Bio says its $402 million offering was completed with the overallotment option fully exercised. The same release reports a 2025 net loss of $77.6 million, up from $36.1 million, and cash of $352.9 million at year-end. ## Latest Belite Bio news 1. 2025-02-07 Financings [Belite Bio sells 258,309 ADSs with warrants for $15,000,004](https://aibio.space/news/belite-bio-sells-258-309-adss-warrants-15-000-004/) Belite Bio is selling 258,309 ADSs and warrants for the same number of ADSs at $58.07 each through Titan Partners Group LLC. The prospectus says the company has recorded net cash outflows from operations since inception. ## Belite Bio at a glance - **Ticker**: BLTE - **Listing**: NASDAQ - **Country**: United States - **Cash, Dec 31, 2025**: $352.9 million ### Related companies - [Incyte](https://aibio.space/companies/incyte/) NASDAQ: INCY - [Innovation Pharmaceuticals](https://aibio.space/companies/innovation-pharmaceuticals/) OTC: IPIX - [vTv Therapeutics](https://aibio.space/companies/vtv-therapeutics/) NASDAQ: VTVT - [Vaxxinity](https://aibio.space/companies/vaxxinity/) OTC: VAXX - [Aoxing Pharmaceutical Company](https://aibio.space/companies/aoxing-pharmaceutical/) OTC: AOXG - [Viskase Holdings](https://aibio.space/companies/viskase/) OTC: VISK - [NanoViricides](https://aibio.space/companies/nanoviricides/) AMEX: NNVC - [Oruka Therapeutics](https://aibio.space/companies/oruka-therapeutics/) NASDAQ: ORKA ### Also on NASDAQ - [Nkarta](https://aibio.space/companies/nkarta/) NKTX - [PMGC Holdings](https://aibio.space/companies/pmgc/) ELAB - [Obsidian Therapeutics](https://aibio.space/companies/obsidian-therapeutics/) OBX - [CNS Pharmaceuticals](https://aibio.space/companies/cns-pharmaceuticals/) CNSP - [Filana Therapeutics](https://aibio.space/companies/filana-therapeutics/) FLNA - [Xencor](https://aibio.space/companies/xencor/) XNCR ## Belite Bio annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$45.4 million](https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/) | [$29.9 million](https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/) | | Net income (loss) | [-$77.6 million](https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/) | [-$36.1 million](https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/) | | Cash from operations | [-$37.0 million](https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/) | [-$29.2 million](https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/) | | Cash and equivalents | [$352.9 million](https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/) | [$31.7 million](https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/) | | Short-term investments | | [$4.5 million](https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $352.9 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Belite Bio Has Belite Bio raised money recently? Our latest story on this, dated Mar 2, 2026: "Belite Bio says it completed a $402 million public offering of ADSs". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/belite-bio-says-completed-402-million-public-offering-adss/). What is the ticker symbol of Belite Bio? Belite Bio, Inc trades under the ticker BLTE on NASDAQ. Where is Belite Bio listed? Belite Bio, Inc is listed on NASDAQ. What is the SEC CIK of Belite Bio? The SEC Central Index Key (CIK) for Belite Bio, Inc is 1889109. Its filings are on SEC EDGAR. How many shares does Belite Bio have outstanding? 39,339,960 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-31. Which country or territory is Belite Bio listed under? Our directory records Belite Bio, Inc under United States. What does Belite Bio do? Our directory classifies Belite Bio, Inc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Belite Bio? The ISIN recorded for Belite Bio, Inc is US07782B1044. Does aibio.space cover Belite Bio? aibio.space lists Belite Bio, Inc among 2,820 public biotech companies and publishes its news here as stories appear. Where is Belite Bio incorporated? SEC records list its state or country of incorporation as E9. Is Belite Bio profitable? Belite Bio, Inc reported a net loss of $77.6 million for the fiscal year ended Dec 31, 2025, and used $37.0 million of cash in operations, per its annual report to the SEC. How much does Belite Bio spend on research and development? $45.4 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Belite Bio have? $352.9 million in cash at Dec 31, 2025, per its 20-F. What is the latest Belite Bio (BLTE) stock news? Our latest story on Belite Bio, dated Mar 2, 2026: "Belite Bio says it completed a $402 million public offering of ADSs". Belite Bio says its $402 million offering was completed with the overallotment option fully exercised. The same release reports a 2025 net loss of $77.6 million, up from $36.1 million, and cash of $352.9 million at year-end. [Source](https://aibio.space/news/belite-bio-says-completed-402-million-public-offering-adss/). Is Belite Bio a smaller reporting company? SEC records list Belite Bio, Inc's filer category as: Large accelerated filer. ## Investor discussion: Belite Bio Members talk about Belite Bio (BLTE). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Belite Bio, newest first. Each line links the filing it comes from. 1. 2026-03-31 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1889109/000110465926037376/tm261133d2_ex99-1.htm) 2. 2026-03-02 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1889109/000110465926021805/tm267429d1_ex99-1.htm) 3. 2025-12-01 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1889109/000110465925117334/tm2532416d3_ex99-1.htm) 4. 2025-11-10 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1889109/000110465925108842/tm2530713d1_ex99-1.htm) 5. 2025-09-08 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1889109/000110465925088050/tm2525484d1_ex99-1.htm) 6. 2025-08-07 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1889109/000110465925075001/tm2522848d1_ex99-1.htm) 7. 2025-05-14 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1889109/000110465925047990/tm2514797d1_ex99-1.htm) 8. 2025-03-17 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1889109/000110465925024128/tm258947d1_ex99-1.htm) 9. 2025-03-17 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1889109/000110465925024131/tm258947d2_ex99-1.htm) 10. 2025-02-07 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1889109/000110465925010252/tm255839-1_424b5.htm) 11. 2025-01-27 Financings Reported a financing. SEC Form 424B7. [Source](https://www.sec.gov/Archives/edgar/data/1889109/000110465925006367/tm254353-2_424b7.htm) 12. 2024-11-04 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1889109/000110465924113607/tm2427379d1_6k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:BLTE on TradingView](https://www.tradingview.com/symbols/NASDAQ-BLTE/). ## SEC filings and registration - **SEC name**: Belite Bio, Inc - **CIK**: 1889109 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: BLTE (Nasdaq) - **State or country of incorporation**: E9 - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 12750 HIGH BLUFF DRIVE SUITE 475, SAN DIEGO, CA, 92130 - **Phone**: 858-246-6240 - **Shares outstanding**: 39,339,960 as of 2025-12-31 (20-F filed 2026-03-31) - **Former names**: BELITE BIO, INC ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1889109/000110465926116685/tm2627719d1_6k.htm) filed 2026-10-19 - [6-K](https://www.sec.gov/Archives/edgar/data/1889109/000110465926105608/tm2624806d1_6k.htm) filed 2026-09-08 - [6-K](https://www.sec.gov/Archives/edgar/data/1889109/000110465926095218/tm2623018d1_6k.htm) filed 2026-08-13 - [6-K](https://www.sec.gov/Archives/edgar/data/1889109/000110465926094040/tm2622827d1_6k.htm) filed 2026-08-11 - [6-K](https://www.sec.gov/Archives/edgar/data/1889109/000110465926073668/tm2617120d1_6k.htm) filed 2026-06-15 - [6-K](https://www.sec.gov/Archives/edgar/data/1889109/000110465926064049/tm2614933d1_6k.htm) filed 2026-05-20 - [6-K](https://www.sec.gov/Archives/edgar/data/1889109/000110465926045989/tm2611999d1_6k.htm) filed 2026-04-21 - [6-K](https://www.sec.gov/Archives/edgar/data/1889109/000110465926037376/tm261133d2_6k.htm) filed 2026-03-31 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001889109), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Belite Bio, Inc is a public biotech or pharmaceutical company listed on NASDAQ under the ticker BLTE, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Belite Bio, Inc - **Ticker**: BLTE - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US07782B1044 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-BLTE/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/belite-bio/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Belite Bio (BLTE) news: offering", 2026-10-31, https://aibio.space/companies/belite-bio/